<DOC>
	<DOCNO>NCT00421031</DOCNO>
	<brief_summary>The purpose study assess efficacy safety 4 dose desvenlafaxine-233 sustained release ( DVS-233 SR ) compare placebo treatment moderate severe vasomotor symptom associate menopause , well influence sleep parameter health outcome indicator .</brief_summary>
	<brief_title>Study Evaluating Safety &amp; Efficacy DVS-223 SR Relief Vasomotor Symptoms Associated With Menopause</brief_title>
	<detailed_description />
	<criteria>1 . Generally healthy , postmenopausal woman ; least 12 month spontaneous amenorrhea least 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL least 6 week postsurgical bilateral oophorectomy ( without hysterectomy ) . 2 . Minimum 7 moderate severe hot flush per day 50 moderate severe hot flush per week screening : Moderate hot flush : warm sensation sweating , disrupt activity . Severe hot flush : hot sensation sweating , disrupts activity . 3 . Subjects must body mass index ( BMI ) less equal 40 use nomograph BMI . 1 . Hypersensitivity venlafaxine ( Effexor Effexor XR ) . 2 . Use oral estrogen , progestin , androgen , SERMcontaining drug product within 8 week prior screen ; use transdermal hormone product within 8 week prior screen ; use vaginal hormone product ( ring , cream , gel ) within 4 week prior screen ; use intrauterine progestin within 8 week prior screen ; use progestin implant estrogen injectables within 3 month prior screen ; use estrogen pellet progestin injectables within 6 month prior screen . 3 . History seizure disorder single childhood febrile seizure .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>